VEGFA and neoplasm: The analysis suggests that bevacizumab, as a targeted therapy, exerts anti-VEGF effects by inhibiting the formation of new tumor blood vessels, reducing their permeability, neutralizing the bioactivity of VEGF, and stabilizing the tumor vascular system.